ACTIVE ENANTIOMERS AND THE SALTS THEREOF FOR TREATING OBESITY.

摘要

The purpose of the invention is to develop three novel drugs S (+)-fenproporex, S (+)-diethylpropion and S (+)-bupropion and the salts thereof presenting important advantages for treating obesity unlike the corresponding racemic drugs. One of the advantages is that only the half of the developed drug of the present invention is used for reaching the same dopaminergic capacity of the racemic active principle. Reducing the drug dosage promotes the reduction of the side effects, amongst which are severe cardiovascular disorders. In addition, the fact of removing the enantiomers with different activities, and in some cases side effects, provides an obesity treatment with a higher quality unlike the drugs applied with racemic active principles.